Taipei, Taiwan

Tse-Ming Hong


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2007-2015

Loading Chart...
6 patents (USPTO):

Title: Tse-Ming Hong: Innovator in Cancer Treatment

Introduction

Tse-Ming Hong is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer treatment through his innovative research and development of new compounds. With a total of 6 patents, his work focuses on creating effective therapeutic agents for combating cancer.

Latest Patents

Among his latest patents, Tse-Ming Hong has developed "Antofine and cryptopleurine derivatives as anticancer agents." This invention provides compounds of Formula (I-IV), along with compositions containing these compounds and methods for their use in cancer treatment. Another notable patent is "Composition for treating cancer and use thereof," which features a cyclic peptide containing the RRXR motif. This invention also includes a composition comprising the cyclic peptide and a pharmaceutical acceptable carrier, along with methods for treating cancer.

Career Highlights

Tse-Ming Hong has worked with esteemed institutions such as National Taiwan University and Advpharma, Inc. His research has been pivotal in advancing the understanding and treatment of cancer, showcasing his dedication to improving patient outcomes through innovative solutions.

Collaborations

Tse-Ming Hong has collaborated with notable colleagues, including Pan-Chyr Yang and Jeremy J W Chen. These partnerships have further enriched his research and contributed to the development of groundbreaking cancer therapies.

Conclusion

Tse-Ming Hong's contributions to cancer treatment through his patents and collaborations highlight his role as a leading inventor in the field. His innovative approaches continue to pave the way for new therapeutic options for patients battling cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…